Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2042-0226
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies ; volume:19 ; number:7 ; day:2 ; month:6 ; year:2022 ; pages:866 ; date:7.2022
Cellular & molecular immunology ; 19, Heft 7 (2.6.2022), 866, 7.2022
- Creator
-
Bullock, Timothy N. J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41423-022-00865-2
- URN
-
urn:nbn:de:101:1-2022082021295669443360
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bullock, Timothy N. J.
- SpringerLink (Online service)
Other Objects (12)
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Mechanismen der Aktivierung von CD40 durch monoklonale Antikörper und löslichen CD40 Liganden und der Nachweis von löslichem CD40 in vivo, einem möglichen Regulator der CD40-CD40 Ligand Interaktion
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Neurotoxicity of novel cancer immunotherapies
Emerging Immunotherapies for Parkinson Disease
Advances in Prostate Cancer Immunotherapies
Implantable Biomaterials for Cancer Immunotherapies
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Mechanismen der Aktivierung von CD40 durch monoklonale Antikörper und löslichen CD40 Liganden und der Nachweis von löslichem CD40 in vivo, einem möglichen Regulator der CD40-CD40 Ligand Interaktion
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Neurotoxicity of novel cancer immunotherapies
Emerging Immunotherapies for Parkinson Disease
Advances in Prostate Cancer Immunotherapies
Implantable Biomaterials for Cancer Immunotherapies
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Mechanismen der Aktivierung von CD40 durch monoklonale Antikörper und löslichen CD40 Liganden und der Nachweis von löslichem CD40 in vivo, einem möglichen Regulator der CD40-CD40 Ligand Interaktion
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Neurotoxicity of novel cancer immunotherapies
Emerging Immunotherapies for Parkinson Disease
Advances in Prostate Cancer Immunotherapies